Yıl: 2021 Cilt: 53 Sayı: 1 Sayfa Aralığı: 5 - 8 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2020.20047 İndeks Tarihi: 24-06-2021

Revaccination in Pediatric Oncology Patients: One Center Experience

Öz:
Objective: After chemotherapy, cancer survivors suffer from acquired immunological defects and become vulnerable to vaccine-preventable diseases. There are no universally approved revaccination guidelines for non-transplanted oncology patients. This study aimed to share our experience of revaccination in childhoodcancer survivors to plan future vaccination schedules.Materials and Methods: This retrospective study was conducted in a Pediatric Oncology Department of a university-affiliated hospital. Patients who were diagnosed with malignancy other than leukemia constituted the study population. Patients were directed for revaccination 6 months after the cessation of treatment. Revaccination was performed according to patients’ vaccination status before chemotherapy and seronegativity.Results: Of the 64 patients in the study, 44 (68.75%) were boys. The mean age at the time of diagnosis and at start of vaccination was 8.8±5.3 years and 10.6±5.1 years, respectively. Hodgkin’s lymphoma was the most common diagnosis. The vaccination schedule of 7 patients was interrupted because of chemotherapy;after completing the missing vaccine doses, the serology of 2 patients was negative for at least 2 antigens. The vaccination schedule of 57 patients was completed before beginning chemotherapy and 52 of them were seronegative for at least 1 antigen. No adverse reactions or life-threatening infections were observedbecause of vaccinations.Conclusion: There are different approaches when vaccinating the oncology patients after chemotherapy. Watching out for the four touchstones mentioned in our study will protect the patient and do no harm.More studies are needed to constitute universal and standardized revaccination guidelines for these patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia, Pa; USA: Lippincott; 2011. Principles of multimodal therapy.
  • 2. Zignol M, Peracchi M, Tridello G, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004; 101: 635-41.
  • 3. Ek T, Mellander L, Andersson B, Abrahamsson J. Immune reconstitution after childhood acute lymphoblastic leukemia in most severely affected in the high-risk group. Pediatr Blood Cancer 2005; 44: 461-8.
  • 4. Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J 2012; 12: 228-43.
  • 5. Crawford NW, Health JA, Ashley D, Downie P, Buttery JP. Survivors of childhood cancer: an Australian audit of vaccination status after treatment. Pediatr Blood Cancer 2010; 54: 128-33.
  • 6. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: 309-18.
  • 7. Han JH, Harmoney KM, Torrez J, et al. Dynamic re-immunization of off-treatment childhood cancer survivors: An Implementation feasibility study. Plos One 2018; 13: e0191804.
  • 8. Succi RC, Farhat CK. Vaccination in special situations. J Pediatr (Rio J) 2006; 82(3 Suppl): S91-100.
  • 9. https://dosyasb.saglik.gov.tr/Eklenti/1117,gbpgenelge2008pdf.pdf?0 (Date of access: 10.3.2019).
  • 10. Avinash KS, Winter MA. Immunization of Children Receiving Immunosuppressive Therapy for Cancer or Hematopoietic Stem Cell Transplantation. Ochsner J 2012; 12: 228-43.
  • 11. Ridgeway D, Wolff LJ, Active immunization of children with leukemia and other malignancies. Leuk Lymphoma 1993; 9: 177-92.
  • 12. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines. Morbidity and Mortality Weekly Report 2010; 59: 1-62.
  • 13. Skinner R, Davies EG, Cant AI, Finn A, Foot A. Royal College of Paediatrics and Child Health (RCPCH) best practice statement on İmmunisation in the immunocompromised child. Int Jour of Infec Dis 2002; 6: 58-9.
  • 14. Garonzi C, Balter R, Tridello G, et al. The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases. Mediterr J Hematol Infect Dis 2020; 12:e2020014.
  • 15. American Academy of Pediatrics. Poliovirus infections. In: Pickering LK, Baker CJ, Kimberlin DW, et al, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics. 2009. pp. 541-45.
  • 16. Lernbecher T, Foster C, Vazquez N, et al. Therapy induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol 1997; 19: 399-417.
  • 17. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 143-9.
  • 18. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89: 3700-07.
  • 19. Recommendations of the Advisory Committee on Immunisation Practices (ACIP): the use of vaccines and immunoglobulins in persons with altered immunocompetence. MMWR Recomm Rep 1993; 42: 1-18.
  • 20. Esposito S, Cecinati V, Brescia L, Principi N. Vaccinations in children with cancer. Vaccine 2010; 28: 3278-84.
  • 21. Sung L, Heurter H, Zokvic K, et al. Practical vaccination guidelines for children with cancer. Paediatr Child Health 2001; 6: 379-83.
  • 22. Ruggiero A, Battista A, Coccia P, Attina G, Riccardi R. How to manage vaccinations in children with cancer. Pediatr Blood Cancer 2011; 57:1104-8.
  • 23. Ariza-Heradia E, Chemaly R. Practical review of immunizations in adult patients with cancer. Hum Vaccin Immunother 2015; 11: 2606-14.
  • 24. Lehrnbecher T, Schubert R, Behl M, et al. Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukemia. Br J Haematol 2009; 147: 700-5.
  • 25. Feldman S, Gigliotti F, Shenep JL, et al. Risk of Haemophilus influenza type b disease in children with cancer and the response of immunocompromised leukemic children to a conjugated vaccine. J Infect Dis 1990; 161: 929-31.
  • 26. Centers for Disease C, Prevention. Recommendation of the advisory committee on immunization practices (ACIP) for use of the quadrivalent meningococcal conjugate vaccine (MenACWYD) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mort Wkly Rep 2011; 60: 1391-2.
  • 27. Loulergue P, Mir O, Alexandre J, Ropert S, Goldwasser F, Launay O. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008; 19: 1658
APA YILMAZBAS N, susam sen h, ocak s (2021). Revaccination in Pediatric Oncology Patients: One Center Experience. , 5 - 8. 10.5152/eurasianjmed.2020.20047
Chicago YILMAZBAS NİMET PINAR,susam sen hilal,ocak suheyla Revaccination in Pediatric Oncology Patients: One Center Experience. (2021): 5 - 8. 10.5152/eurasianjmed.2020.20047
MLA YILMAZBAS NİMET PINAR,susam sen hilal,ocak suheyla Revaccination in Pediatric Oncology Patients: One Center Experience. , 2021, ss.5 - 8. 10.5152/eurasianjmed.2020.20047
AMA YILMAZBAS N,susam sen h,ocak s Revaccination in Pediatric Oncology Patients: One Center Experience. . 2021; 5 - 8. 10.5152/eurasianjmed.2020.20047
Vancouver YILMAZBAS N,susam sen h,ocak s Revaccination in Pediatric Oncology Patients: One Center Experience. . 2021; 5 - 8. 10.5152/eurasianjmed.2020.20047
IEEE YILMAZBAS N,susam sen h,ocak s "Revaccination in Pediatric Oncology Patients: One Center Experience." , ss.5 - 8, 2021. 10.5152/eurasianjmed.2020.20047
ISNAD YILMAZBAS, NİMET PINAR vd. "Revaccination in Pediatric Oncology Patients: One Center Experience". (2021), 5-8. https://doi.org/10.5152/eurasianjmed.2020.20047
APA YILMAZBAS N, susam sen h, ocak s (2021). Revaccination in Pediatric Oncology Patients: One Center Experience. Eurasian Journal of Medicine, 53(1), 5 - 8. 10.5152/eurasianjmed.2020.20047
Chicago YILMAZBAS NİMET PINAR,susam sen hilal,ocak suheyla Revaccination in Pediatric Oncology Patients: One Center Experience. Eurasian Journal of Medicine 53, no.1 (2021): 5 - 8. 10.5152/eurasianjmed.2020.20047
MLA YILMAZBAS NİMET PINAR,susam sen hilal,ocak suheyla Revaccination in Pediatric Oncology Patients: One Center Experience. Eurasian Journal of Medicine, vol.53, no.1, 2021, ss.5 - 8. 10.5152/eurasianjmed.2020.20047
AMA YILMAZBAS N,susam sen h,ocak s Revaccination in Pediatric Oncology Patients: One Center Experience. Eurasian Journal of Medicine. 2021; 53(1): 5 - 8. 10.5152/eurasianjmed.2020.20047
Vancouver YILMAZBAS N,susam sen h,ocak s Revaccination in Pediatric Oncology Patients: One Center Experience. Eurasian Journal of Medicine. 2021; 53(1): 5 - 8. 10.5152/eurasianjmed.2020.20047
IEEE YILMAZBAS N,susam sen h,ocak s "Revaccination in Pediatric Oncology Patients: One Center Experience." Eurasian Journal of Medicine, 53, ss.5 - 8, 2021. 10.5152/eurasianjmed.2020.20047
ISNAD YILMAZBAS, NİMET PINAR vd. "Revaccination in Pediatric Oncology Patients: One Center Experience". Eurasian Journal of Medicine 53/1 (2021), 5-8. https://doi.org/10.5152/eurasianjmed.2020.20047